Hims & Hers Health, Inc. (HIMS)
| Market Cap | 12.27B |
| Revenue (ttm) | 1.78B |
| Net Income (ttm) | 164.40M |
| Shares Out | 223.83M |
| EPS (ttm) | 0.68 |
| PE Ratio | 80.42 |
| Forward PE | 68.65 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 23,607,075 |
| Open | 53.51 |
| Previous Close | 53.52 |
| Day's Range | 52.88 - 55.37 |
| 52-Week Range | 13.47 - 72.98 |
| Beta | 1.85 |
| Analysts | Hold |
| Price Target | 37.67 (-31.3%) |
| Earnings Date | May 5, 2025 |
About HIMS
Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supp... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for HIMS stock is "Hold." The 12-month stock price forecast is $37.67, which is a decrease of -31.30% from the latest price.
News
Avoid These Dividend Disasters Before It's Too Late
Dividend stocks are facing many big risks. The high interest rates, trade war, and AI revolution could lead to many dividend cuts. I discuss what this all means for dividend investors.
Hims & Hers Introduces 6-Month Wegovy® New Customer Offer
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) today announced eligible customers can access 6 months of prescription-only Wegovy® at a new, affordable price, making proven obes...
Hims & Hers: After A Bout Of Uncertainty, Upside Remains
Hims & Hers continues to deliver strong subscriber and revenue growth, with Q1 2025 revenue up 111% year-over-year and operating leverage improving. The business model's shift to a subscription platfo...
Hims & Hers: Growth, Strategic Partnerships, And Operational Leverage (Upgrade)
Hims & Hers Health's rapid revenue and subscriber growth, plus improving cash generation, highlight strong business momentum and brand strength. Gross margins have declined due to lower-margin obesity...
Hims & Hers stock price nears crucial level: is it a buy or sell?
Hims & Hers stock price has surged and is nearing its all-time high as investors bet that its strong momentum will continue in the coming years. HIMS shares surged by almost 16% on Tuesday, reaching i...
50% Upside For HIMS Stock?
Hims & Hers (NASDAQ:HIMS), a telehealth platform with a market capitalization of $14 billion, has seen its stock rise by 150% this year. The stock now trades at over 10x trailing revenues, raising que...
Hims & Hers Health Stock: A Rare High-Growth Value Play In Plain Sight
Rarely I see high-growth, value plays in the market. I think Hims & Hers Health is such a rare case: a world-class, high-growth company still being valued as a risky startup. A DCF model based on 2030...
Hims & Hers: Still Undervalued For These 2 Reasons
Hims' operating leverage was outstanding at 5:1 over revenue growth. This is irrefutable proof of a scalable business. Hims' new TAMs should provide billions to the top line, hundreds of millions to t...
Hims & Hers: Short-Lived Turbulence To Be Followed By New Phase Of Profitable Growth
Hims & Hers delivered impressive Q1 2025 results, with 111% y/y revenue growth and 38% y/y subscriber growth, driven by strong uptake of personalized GLP-1 offerings. Despite a projected Q2 revenue de...
Hims & Hers: Wegovy Deal Opens New Growth Chapter - Missed The Rally? Selling Puts Could Yield 30%
Hims & Hers Health rebounded from a 60% stock drop by partnering with Novo Nordisk, offering Wegovy at a competitive price, boosting accessibility and growth. Q1 earnings were exceptional with 111% Yo...
Hims & Hers Health, Inc. Prices Upsized $870.0 Million Convertible Senior Notes Offering to Accelerate Global Expansion and Utilization of AI in Healthcare
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS) today announced the pricing of its offering of $870,000,000 aggregate principal amount of 0.00% co...
Hims & Hers Stock's 100% Surge Is Squeezing Shorts And It Might Just Be Getting Started
If short sellers were hoping for a flop from Hims & Hers Health Inc. HIMS, they may want to check their risk management settings. The telehealth disruptor dropped first-quarter earnings after the bell...
Hims & Hers: The Road To Blue Chip Status
Personalized subscribers grew 136% YoY, reflecting a fundamental shift towards precision medicine. Despite declining gross margins, HIMS achieved 13pp of operating leverage in Q1. This is by far HIMS'...
Top 3 Health Care Stocks That Could Sink Your Portfolio In Q2
As of May 8, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Hims & Hers Soars Again--Explosive Growth Meets Lofty Expectations
Hims & Hers stock has surged due to impressive quarterly results, rapid weight-loss product expansion, and a strategic Novo Nordisk partnership. Despite trading at a high valuation, technical indicato...
Hims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Accelerate Global Expansion and Utilization of AI in Healthcare
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS) today announced its intention to offer, subject to market and other conditions, $450 million aggre...
Hims & Hers Appoints AI Expert and Former President and CTO at Cruise as Chief Technology Officer
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the appointment of Mo Elshenawy, a proven technology executive with dee...
Hims & Hers: 2030 Guidance Indicates Big Upside
Management's 2030 guidance includes $6.5 billion in revenue and $1.3 billion in adjusted EBITDA, focusing on personalized healthcare and geographic expansion. Anticipating management's guidance for 20...
Hims & Hers: Short Squeeze Or Strong Fundamentals? (Rating Downgrade)
Hims & Hers Health, Inc. Q1 results beat the Street's expectations, as I anticipated in February. The company reaffirmed FY 2025 guidance and increased the EBITDA range for the year. That said, I beli...
Hims & Hers Health: Healthcare Disruptor Building A Durable Moat (Initiate With Buy)
Hims & Hers Health reported strong Q1 '25 earnings, with 111% YoY sales growth and 38% subscriber growth. The company boasts over a 70% gross margin, 90% recurring revenue, and a compelling flywheel e...
2 Reasons Hims & Hers Will Break $50s - Buy Post Earnings
Hims & Hers Health, Inc. impressed with strong Q1 earnings, subscriber growth, and a promising partnership with Novo Nordisk, but didn't guide as well as we all hoped. The two reasons I'm buying are 1...
HIMS Earnings Rally, Guidance Powers CEG, DASH Moves Lower
Hims & Hers (HIMS) rallied this morning after earnings, reversing initial selling action following the report. Diane King Hall believes a huge jump in revenue and its Wegovy deal are behind the positi...
Hims & Hers: Strong Q1 Masks Problematic Long-Term Value Proposition
Hims & Hers Health, Inc.'s Q1 2025 earnings show impressive growth, with revenues up 111% year-on-year and net income rising significantly, but HIMS shares dropped 8% pre-market. The company's success...
HIMS Growth Potential, Weight-loss Drug Pipeline
Raul Shah says Hims & Hers (HIMS) latest earnings report was a win for two reasons: A lot of operating leverage and expanding growth. Raul believes HIMS guidance was "implausible" in his estimation, a...
Hims & Hers Health, Inc. (HIMS) Q1 2025 Earnings Call Transcript
Hims & Hers Health, Inc. (NYSE:HIMS) Q1 2025 Earnings Conference Call May 5, 2025 5:00 PM ET Company Participants Bill Newby - Head of Investor Relations Andrew Dudum - Co-Founder and Chief Executive...